[177Lu]Lu-PSMA-617 in patients with PSMA-positive metastatic androgen pathway modulator-naive/sensitive prostate cancer (PSMAddition): a phase 3 randomised, controlled trial

Overview of attention for article published in The Lancet, August 2026

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (99th percentile)
High Attention Score compared to outputs of the same age and source (91st percentile)

Mentioned by

news: 12 news outlets
blogs: 2 blogs

twitter: 33 X users
bluesky: 2 Bluesky users

Readers on

mendeley: 4 Mendeley

So far, Altmetric has seen 36 X posts from 33 X users, with an upper bound of 127,835 followers.

RT @APCCC_Lugano: 🚨 Could radioligand therapy be moving into the frontline setting for metastatic hormone-sensitive prostate cancer? Artic…

[177Lu]Lu-PSMA-617 in patients with PSMA-positive metastatic androgen pathway modulator-naive/sensitive prostate cancer (PSMAddition): a phase 3 randomised, controlled trial - The Lancet https://t.co/zuyeBmxXAJ

[Articles] [177Lu]Lu-PSMA-617 in patients with PSMA-positive metastatic androgen pathway modulator-naive/sensitive prostate cancer (PSMAddition): a phase 3 randomised, controlled trial https://t.co/9pVKr5yFfA

This page shows the most recent X posts that mention this research output. Click here to find out how to access more activity, including 32 additional X posts.